Navigation Links
Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events
Date:6/13/2008

Paris, France, Friday 13 June 2008: Certain cardiovascular disease (CVD) risk factors and rheumatoid arthritis (RA) disease factors have a similar effect on an RA patient's risk of experiencing myocardial infarction (MI) or stroke, according to a new study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

The researchers studied 10,870 RA patients for a median of 24 months across two cohorts - patients with active RA and those with prior experience of CVD. Cox regression models revealed that the CVD risk factors leading to an increased relative risk of MI or stroke were: non-Caucasian ethnicity (relative risk (RR) 1.26), body mass index (RR 1.25), prior MI (RR 1.75), and any current tobacco use (RR 1.92). The RA disease factors leading to an increased relative risk of MI or stroke were: nodules (RR 1.44), Health Assessment Questionnaire Disability Index (HAQ-DI) (RR 1.20 per each point increase) and the Clinical Disease Activity Index (CDAI) (RR 1.06 per each point increase). The area under the receiver operating characteristic curve (c-statistic) of the CVD risk factor and RA disease factor models (adjusting for age and gender) were both calculated as 0.75, demonstrating a comparable relationship with CVD endpoints for both RA and CVD risk factors..

Lead investigator, Professor Daniel H Solomon of Brigham and Women's Hospital and Harvard Medical School, Boston, USA, said: "It has been established that people with RA are more likely to experience cardiovascular disease or complications than the general population, but our research examines the importance of RA-specific factors compared with traditional cardiovascular risk factors. We have shown that having more high risk RA-specific risk factors increases the CVD risk to a rate similar to that of traditional cardiovascular risk factors. We hope that the results of our study lead to more robust clinical prediction rules for CVD outcomes in RA along with appropriate management and treatment options for the future."

All data were taken from the Consortium of Rheumatology Researchers of North America, Inc. (CORRONA) independent registry, the largest physician-based RA registry in the US, which carries information on over 15,000 patients with RA and other rheumatic conditions. Records for patients who had made at least two visits to healthcare facilities were selected and information about CVD risk factors, with RA disease factors drawn from baseline questionnaires.

CVD outcomes included MI, stroke and transient ischemic attack, reported and then confirmed by the treating rheumatologist. CVD risk factors included a history of coronary artery disease or MI, diabetes, hypertension, family history of premature MI, body mass index, dyslipidemia (assessed as use of a lipid-lowering agent), non-Caucasian ethnicity, and current tobacco use.

RA disease factors included duration of RA, rheumatoid factor status, HAQ, CDAI, subcutaneous nodules, Sjogrens (an autoimmune condition associated with arthritis), tender joint count, swollen joint count, and total joint replacements. These variables were assessed as predictors of CVD outcomes in separate Cox regression models, with age and gender included in both. Finally, the discriminatory value of these variables was assessed by calculating the area under the receiver operating characteristic curve (C statistic) in logistic regression.


'/>"/>

Contact: Rory Berrie / Camilla Dormer
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
2. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
3. Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis
4. Biogen Idecs baminercept alfa shows promise in patients with rheumatoid arthritis
5. Golimumab Eases Rheumatoid Arthritis Symptoms
6. Researchers uncover higher prevalence of periodontal disease in rheumatoid arthritis patients
7. Drinking Cuts Rheumatoid Arthritis Risk
8. Regular tipple may curb risk of rheumatoid arthritis
9. American College of Rheumatology presents recommendations for rheumatoid arthritis therapy
10. Increased incidence of melanoma found in rheumatoid arthritis patients treated with methotrexate
11. Breast-feeding Might Shield Women From Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology: